Table 2.
Comparison in Immune biomarkers of septic patients based upon 28-day mortality.
| Variables | Overall population (n=81) | Survivors (n=68) | Non-survivors (n=13) | P value |
|---|---|---|---|---|
| Inflammatory markers | ||||
| PCT (ng/mL) | 1.3 (5) | 0.97 (4) | 3.9 (11) | 0.06 |
| CRP (mg/dL) | 119.29 (132.55) | 106.451 (08.61) | 166.62 (165.19) | 0.077 |
| IL-6 (pg/ml) | 35.8 (80.13) | 34.55 (88.93) | 50.15 (74.65) | 0.532 |
| IL-8 (pg/ml) | 101 (109.5) | 97.5 (112.5) | 123 (206) | 0.483 |
| IL-10 (pg/ml) | 5.95 (12.98) | 5.9 (14.4) | 9.05 (8.8) | 0.413 |
| TNF-α (pg/ml) | 16.3 (13.2) | 16 (13) | 23.6 (14) | 0.03 |
| Immune parameters | ||||
| C3 (g/L) | 0.871 (0.385) | 0.87 (0.401) | 0.907 (0.463) | 0.949 |
| C4 (g/L) | 0.18 (0.12) | 0.18 (0.156) | 0.153 (0.105) | 0.088 |
| IgA (g/L) | 2.19 (1.47) | 2.29 (2) | 2.58 (2) | 0.748 |
| IgG (g/L) | 8.05, 4.3 | 7.63 (4.72) | 8.84 (7.75) | 0.463 |
| IgM (g/L) | 0.61 (0.48) | 0.62 (0.6) | 0.5 (0.45) | 0.081 |
| Lymphocyte subsets | ||||
| WBC (cells/mm3) | 9240 (7462.5) | 9355 (7667) | 7400 (6543) | 0.169 |
| NG (cells/mm3) | 7.53 (8.11) | 7.1 (7.89) | 7.59 (8.85) | 0.364 |
| NK (cells/mm3) | 62 (75.3) | 78.5 (84) | 41 (61) | 0.066 |
| LY (cells/mm3) | 742 (639.5) | 878 (650.5) | 633 (417.8) | 0.068 |
| CD3+T (cells/mm3) | 572.56 ± 247.1 | 627.6 ± 290.7 | 448.6 ± 195 | 0.037 |
| CD4+T (cells/mm3) | 303.1 ± 80.15 | 310 ± 78.94 | 260.84 ± 87.08 | 0.046 |
| Percentage of mTOR+/CD4+ T cells (%) | 23.97 ± 8.87 | 23.69 ± 9.83 | 29.6 ± 6.5 | 0.026 |
| Percentage of T-bet+/CD4+ T cells (%) | 12.41 (5.56) | 12.46 (5.24) | 9.5(5.71) | 0.019 |
| Percentage of IFN-γ+/CD4+ T cells (%) | 12.06 (9.83) | 13.27 (10.11) | 5.24 (7.08) | 0.001 |
| Percentage of Granzyme B+/CD4+ T cells (%) | 16.59 ± 7.64 | 17.04 ± 8.33 | 15.47 ± 5.31 | 0.516 |
| Percentage of PD-1+/CD4+ T cells (%) | 17.67 ± 5.38 | 17.04 ± 5.30 | 20.97 ± 4.76 | 0.015 |
| CD8+T | 172 (149.3) | 180 (159.5) | 150 (100) | 0.043 |
| Percentage of mTOR+/CD8+ T cells (%) | 29.79 ± 8.64 | 29.52 ± 9.17 | 30.92 ± 7.09 | 0.604 |
| Percentage of T-bet+/CD8+ T cells (%) | 3.01 (2.99) | 3.12 (3.18) | 2.84 (1.558) | 0.748 |
| Percentage of IFN-γ+/CD8+ T cells (%) | 14.3 (9.7) | 15.3 (9.95) | 14.81 (11.44) | 0.969 |
| Percentage of Granzyme B+/CD8+ T cells (%) | 32.73 ± 14.75 | 32.65 ± 13.77 | 30.99 ± 11.44 | 0.648 |
| Percentage of PD-1+/CD8+ T cells (%) | 12.5(8.36) | 11.25 (7.83) | 15 (8.35) | 0.012 |
| CD4+T/CD8+T | 1.65 (1.36) | 1.59 (1.38) | 2.18 (1.9) | 0.361 |
| B cells (cells/mm3) | 84 (171.25) | 90.5 (150) | 55 (85) | 0.285 |
PCT, procalcitonin; CRP, C-reactive protein; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; TNF-α, Tumor necrosis factor; C3, complement factor 3; C4, complement factor 4; Ig, immunoglobulin; WBC, white blood cell; NG, neutrophilic granulocyte; NK, natural killer cell; LY, Lymphocyte. Continuous variables are expressed as the median and interquartile range, other data are raw numbers (%). P value for the comparison between Survivor and Non- Survivor group.